Oppenheimer raised the firm’s price target on Ligand (LGND) to $145 from $142 and keeps an Outperform rating on the shares following quarterly results. Ligand remains in early stages of executing their royalty strategy, and the firm expects continued execution across the portfolio, further supported by deal-making throughout 2025.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand Pharma’s Strong Q1 Performance and Strategic Moves Justify Buy Rating with $135 Price Target
- Ligand Pharmaceuticals Reports Strong Q1 2025 Revenue Growth
- Ligand Pharmaceuticals Reports Strong Q1 2025 Earnings
- Positive Outlook for Ligand Pharma: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- Ligand sees FY25 adjusted EPS $6.00-$6.25, consensus $6.11